Top Industry Leaders in the Alopecia Drugs Market
Latest Alopecia Drugs Companies Updates:
Sun Pharma, a leading Indian pharmaceutical company, acquired Concert Pharmaceuticals in October 2023 for $576 million.This move brings Concert's promising oral drug, deuruxolitinib, under Sun Pharma's wing. Deuruxolitinib is in late-stage trials for alopecia areata and could be the first oral treatment approved for the condition in the US.
In July 2023, Pfizer received FDA approval for LITFULO™ (ritlecitinib), the first-ever systemic therapy for severe alopecia areata approved for adults and adolescents aged 12 and above.This oral medication offers new hope for individuals with advanced alopecia areata who haven't responded to topical treatments.
Pfizer is also seeking approval for LITFULO in other countries and for other hair loss conditions like vitiligoLegacy Healthcare, a Swiss biopharmaceutical company, is making waves with its lead drug candidate, Coacillium, for treating moderate to severe alopecia areata in children and adolescents.
Coacillium is a botanical drug derived from a plant extract, offering a potential alternative to existing treatments with potentially fewer side effects.Legacy Healthcare has garnered media attention and is actively participating in clinical trials for Coacillium, raising hopes for a novel treatment option in the future.
List of Alopecia Drugs Key companies in the market:
- Mylan N.V
- Aurobindo Pharma
- GlaxoSmithKline plc
- Cipla Limited
- Johnson & Johnson Services
- Merck & Co. Inc
- Sun Pharmaceuticals Industries Ltd
- Dr Reddy's Laboratories Ltd
